Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a vaccine stop pancreatic cancer before it starts?

NCT ID NCT05013216

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 01, 2026 · Updated 4 times

Summary

This early-stage study tests a vaccine designed to train the immune system to attack cells with a mutated KRAS gene, which is common in pancreatic cancer. The vaccine is given to people at high risk due to family history or pancreatic cysts. The main goals are to see if the vaccine is safe and whether it triggers an immune response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
KRAS peptide vaccine with poly-ICLC (Hiltonol) adjuvant
What this could lead to
If successful, this could lead to a vaccine that prevents pancreatic cancer in high-risk individuals.
What could go wrong
This is a very early phase 1 study with only 37 participants, so it's too soon to know if the vaccine works. Side effects are possible, and the immune response may not be strong enough to prevent cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH-RISK CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic neoplasm malignant pancreatic neoplasm prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIGH-RISK CANCER PANCREATIC CANCER

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Sidney Kimmel Comprehensive Cancer Center

    RECRUITING

    Baltimore, Maryland, 21231, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.